EPI-506 (ralaniten Acetate), a Novel Androgen Receptor (AR) N-terminal Domain (NTD) Inhibitor, in Men with Metastatic Castration-Resistant Prostate Cancer (mcrpc): Phase 1 Update on Safety, Tolerability, Pharmacokinetics and Efficacy
Annals of oncology(2017)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined